Effect of paliperidone palmitate long-acting injection on the expression of miR-132 and miR-320 in serum of schizophrenic patients
10.3760/cma.j.issn.1008-6706.2019.15.018
- 白话标题: 棕榈酸帕利哌酮对精神分裂症患者血清微小RNA-132和微小RNA-320表达的影响
- 作者:
Na WEN
1
;
Xiujuan PAN
作者信息
1. Department of Psychiatry, Wenzhou Kangning Hospital, Wenzhou, Zhejiang 325000, China
- 出版类型:Journal Article
- 关键字:
Schizophrenia;
Paliperidone palmitate;
Clinical symptoms;
MicroRNA
- 来源:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(15):1862-1865
- 国家China
- 语言:Chinese
-
摘要:
Objective:To investigate the therapeutic effect of long-acting paliperidone palmitate on schizophrenia and the expression of miR-132 and miR-320 in serum of patients with schizophrenia.
Methods:From January 2016 to December 2018, 68 patients with schizophrenia in Wenzhou Kangning Hospital were selected as treatment group.Sixty healthy people were selected as control group.The blood was taken before treatment and 12 months after treatment.The positive and negative symptom scales (PANSS) was recorded and evaluated, and the effect of long-acting injection of paliperidone palmitate on the expression of miR-132 and miR-320 in serum of patients with schizophrenia was detected by RT-PCR.
Results:Three months after treatment, the PANSS scores of the treatment group were significantly lower than those of the case group [(60.2±5.4)points vs.(84.5±4.7)points, t=12.02, 22.52, 27.16, 33.32, all P<0.01]. With the prolongation of treatment time, the treatment effect was most obvious at 12 months[(38.2±1.8)points]. The results of RT-PCR showed that compared with the control group [(1.74±0.92)%, (1.43±1.01)%], the expression of serum miR-132 and miR-320 in the treatment group was significantly decreased [(0.47±0.32)%, (0.53±0.37)%, t=13.96, 14.93, all P<0.01]. The long-acting injection of paliperidone palmitate significantly increased the expression of miR-132 and miR-320 in serum of patients with schizophrenia[(0.96±0.58), (1.16±1.07), t=11.08, 8.45, all P<0.01].
Conclusion:Long-acting paliperidone palmitate has a certain therapeutic effect on schizophrenia and can up-regulate the expression of miR-132 and miR-320 in serum of patients with schizophrenia.
